According to GlobalData’s medical device pipeline database, 51 Colorectal Cancer Screening Tests devices are in various stages of development globally. GlobalData’s report Colorectal Cancer Screening Tests provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, 41 are in active development, while the remaining 12 are in an inactive stage of development. There are nine products in the early stages of development, and the remaining 32 are in the late stages of development.
In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Colorectal cancer screening tests are carried to monitor bowel health of at-risk individuals, typically the elderly, in order to be able to detect and treat colorectal cancer in a timely manner. This Colorectal cancer screening testing market includes sub-segments Guaiac Fecal Occult Blood Test (gFOBT) Kits, Immunochemical Fecal Occult Blood Test (iFOBT or FIT) Kits, Fecal DNA Test Kits, and Other Colorectal Cancer Screening Tests.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Colorectal Cancer Screening Tests pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Colorectal Cancer Screening Tests devices. Overall, most of these Colorectal Cancer Screening Tests pipeline devices are being developed by private entities.
Key players involved in the active development of Colorectal Cancer Screening Tests include Guardant Health, VolitionRX, Mainz Biomed, mBioSys, Neuome Peptides, Oncodiag, Oncomark, Prenetics, Preora Healthcare and QuantuMDx Group.
For a complete picture of the developmental pipeline for Colorectal Cancer Screening Tests devices, buy the report here.